|
COPYRIGHT 2005 International Medical News Group
ATLANTA -- The new adolescent / adult formula tetanus-diphtheria-acellular pertussis vaccine should be routinely administered to 11- to 12-year-olds, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted at its summer meeting.
Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (Tdap) products were licensed for single-dose use earlier this year: GlaxoSmithKline's Boostrix, approved for ages 10-18 years, and Sanofi-Pasteur's Adacel, for ages 11-64 years. ACIP's recommendation--which is not official until approved and published by the CDC also calls for catch-up use of Tdap...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
